Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FENC

FENC - Fennec Pharmaceuticals Inc Stock Price, Fair Value and News

$7.46-0.39 (-4.97%)
Market Closed

38/100

FENC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

38/100

FENC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.71

Target 3M

$7.41

Target 6M

$7.17

FENC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FENC Price Action

Last 7 days

-3.1%

Last 30 days

-3.0%

Last 90 days

-10.4%

Trailing 12 Months

14.8%

FENC RSI Chart

FENC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FENC Valuation

Market Cap

209.8M

Price/Earnings (Trailing)

-30.22

Price/Sales (Trailing)

5.41

EV/EBITDA

81.58

Price/Free Cashflow

-26.27

FENC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.71

Target 3M

$7.41

Target 6M

$7.17

FENC Fundamentals

FENC Revenue

Revenue (TTM)

38.8M

Rev. Growth (Yr)

78.69%

Rev. Growth (Qtr)

29.11%

FENC Earnings

Earnings (TTM)

-6.9M

Earnings Growth (Yr)

88.88%

Earnings Growth (Qtr)

79.76%

FENC Profitability

EBT Margin

-0.18%

Return on Equity

154.5%

Return on Assets

-14.09%

Free Cashflow Yield

-3.81%

FENC Investor Care

Shares Dilution (1Y)

2.50%

Diluted EPS (TTM)

-0.22

FENC Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202530.9M33.3M38.8M0
202445.0M48.9M49.3M47.5M
20233.2M6.5M13.0M21.3M
20220161.0K59.0K1.5M
202100230.0K174.0K
202000271.0K287.0K
2019355.0K392.0K361.0K315.0K
2018103.0K171.0K256.0K348.0K
201711.0K13.0K26.0K47.0K
201605.0K7.0K8.0K
20155.0K3.0K4.0K3.0K
201402.0K2.0K2.0K
201320.5K011.3K2.0K
201244.5K46.0K30.0K26.5K
201100043.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Fennec Pharmaceuticals Inc

FENC
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
 CEO
 WEBSITEfennecpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES36

Fennec Pharmaceuticals Inc Frequently Asked Questions

FENC is the stock ticker symbol of Fennec Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Fennec Pharmaceuticals Inc is 209.75 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FENC's fair value in chart for subscribers.

The fair value guage provides a quick view whether FENC is over valued or under valued. Whether Fennec Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Fennec Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FENC.

As of Wed Jan 28 2026, FENC's PE ratio (Price to Earnings) is -30.22 and Price to Sales (PS) ratio is 5.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FENC PE ratio will change depending on the future growth rate expectations of investors.